Medical technology company Stryker has secured pre-market approval from the US Food and Drug Administration (FDA) for the use of its Surpass Streamline Flow Diverter in treating unruptured large and giant wide-neck intracranial aneurysms.

The flow diverter has been designed as a small cobalt chromium braided stent for directing blood flow inside an intracranial artery, away from a weakened blood vessel sac or aneurysm.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

This blood flow diversion is meant to occlude the aneurysm over time, thereby decreasing the risk of rupture in the future.

“Stryker’s flow-diverting stent is said to be equipped to address aneurysms in the neck region by reliably opening and delivering consistent mesh density for the occlusion and maintenance of perforator artery patency.”

Surpass Streamline, which is already marketed in other international countries, is the second such device to obtain the US regulatory approval.

Stryker Neurovascular division president Mark Paul said: “The PMA approval of Surpass Streamline Flow Diverter in the US is an important milestone for the division.

“It expands our commercial footprint into the flow diversion market and reinforces our commitment to complete stroke care for patients suffering from cerebrovascular disease.”

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The treatment of unruptured aneurysms is considered more challenging due to their location and surrounding anatomy.

Stryker’s flow-diverting stent is said to be equipped to address these aneurysms in the neck region by reliably opening and delivering consistent mesh density for the occlusion and maintenance of perforator artery patency.

The FDA approval is based on clinical outcomes obtained during the prospective, multi-centre SCENT investigational device exemption (IDE) clinical trial.

According to the results, the trial met both primary and secondary endpoints, as well as demonstrated single stent efficacy with the Surpass Streamline Flow Diverter.

SCENT IDE trial co-principal investigator Ricardo Hanel said: “The ability to resheath, reposition and recapture the device without losing distal wire position is a significant advantage for Surpass.”

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact